AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27110376 — intervention group
Group type: COMPARATOR
Intervention: Control (standard home CR)
Number of subjects: 70
Study 27110377 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine non-invasive management with optimal medical therapy
Number of subjects: 60
Study 27110377 — intervention group
Group type: COMPARATOR
Intervention: Routine invasive management
Number of subjects: 60
Study 27110385 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg weekly with background methotrexate
Number of subjects: 646
Study 27110385 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg bi-weekly with background methotrexate
Number of subjects: 646
Study 27110385 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept or adalimumab with background methotrexate
Number of subjects: 646
Study 27110692 — intervention group
Group type: EXPERIMENTAL
Intervention: cNEP
Number of subjects: 54
Study 27110692 — intervention group
Group type: COMPARATOR
Intervention: no-cNEP
Number of subjects: 54
Study 27110693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clipping with a clip distance of 3 mm
Number of subjects: 1717
Study 27110693 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic clipping (control)
Number of subjects: 1717
Study 27110693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clipping
Number of subjects: 1717
Study 27110693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clipping strategy
Number of subjects: 1717
Study 27110997 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety patients
Number of subjects: 0
Study 27110997 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 27111235 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells with defined CD4+:CD8+ composition
Number of subjects: 29
Study 27111235 — intervention group
Group type: EXPERIMENTAL
Intervention: High CAR-T cell doses and tumor burden
Number of subjects: 29
Study 27111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified CAR-T cell dosing based on BM disease burden
Number of subjects: 29
Study 27111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of fludarabine to the lymphodepletion regimen
Number of subjects: 29
Study 27111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of serum biomarkers
Number of subjects: 29
Study 27111344 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon and ribavirin for 24 weeks
Number of subjects: 107
Study 27111344 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon and ribavirin for 48 weeks
Number of subjects: 107
Study 27111344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs administered during follow-up)
Number of subjects: 107
Study 27111344 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon and ribavirin for both 24 and 48 weeks
Number of subjects: 107
Study 27112038 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative tight glycemic control
Number of subjects: 980
Study 27112038 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 980
Study 27112038 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe hypoglycemia
Number of subjects: 980
Study 27112106 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 273
Study 27112106 — intervention group
Group type: COMPARATOR
Intervention: Usual care, nonpharmacologic, or pharmacologic interventions (Control)
Number of subjects: 273
Study 27112193 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based screening
Number of subjects: 1400000
Study 27112193 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 1400000
Study 27112193 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy volumes
Number of subjects: 1400000
Study 27112193 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up tests and procedures
Number of subjects: 1400000
Study 27112606 — intervention group
Group type: EXPERIMENTAL
Intervention: <55 years old group
Number of subjects: 14854
Study 27112606 — intervention group
Group type: EXPERIMENTAL
Intervention: 55-64 years old group
Number of subjects: 14854
Study 27112606 — intervention group
Group type: EXPERIMENTAL
Intervention: 65-74 years old group
Number of subjects: 14854
Study 27112606 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥75 years old group
Number of subjects: 14854
Study 27112606 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups
Number of subjects: 14854
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel use
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins use
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct percutaneous coronary intervention (PCI)
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers use
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate within 7 days
Number of subjects: 5257
Study 27112607 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or treatment withdrawal due to terminal status
Number of subjects: 5257
Study 27113199 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies used to introduce and encourage uptake of a quality improvement intervention.
Number of subjects: 0
Study 27113199 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies tailored to fit local context.
Number of subjects: 0
Study 27113209 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) procedure
Number of subjects: 2500
Study 27113466 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-OH15 module
Number of subjects: 572
Study 27113680 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-monitoring wristbands
Number of subjects: 8
Study 27113680 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 8
Study 27114712 — intervention group
Group type: EXPERIMENTAL
Intervention: SIJ fusion using iFuse Implant System(®)
Number of subjects: 0
Study 27114712 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 0
Study 27115061 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPII
Number of subjects: 184
Study 27115431 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott HCV core antigen (cAg) assay with a clinical cutoff of 10 fmol/l
Number of subjects: 631
Study 27115431 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott HCV core antigen (cAg) assay
Number of subjects: 631
Study 27115431 — intervention group
Group type: COMPARATOR
Intervention: Roche High-Pure system/COBAS
Number of subjects: 631
Study 27116013 — intervention group
Group type: EXPERIMENTAL
Intervention: MLS(®) laser therapy (LT) - 6 sessions, beam area 19.635 cm², 0.168 W/cm², 4 J/cm², starting at fraction 20 of radiotherapy
Number of subjects: 79
Study 27116013 — intervention group
Group type: COMPARATOR
Intervention: Standard skin care (Control)
Number of subjects: 79
Study 27116013 — intervention group
Group type: EXPERIMENTAL
Intervention: MLS(®) laser therapy (LT)
Number of subjects: 79
Study 27116183 — intervention group
Group type: EXPERIMENTAL
Intervention: Foretinib 60 mg po daily
Number of subjects: 45
Study 27116379 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (self-administered for 62.3% of attacks, healthcare professional-administered for 37.7%)
Number of subjects: 42
Study 27116910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 6136
Study 27117781 — intervention group
Group type: EXPERIMENTAL
Intervention: African descent (AD)
Number of subjects: 1172
Study 27117781 — intervention group
Group type: COMPARATOR
Intervention: European descent (ED)
Number of subjects: 1172
Study 27117828 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 97
Study 27117828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma sRAGE levels
Number of subjects: 97
Study 27117828 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 97
Study 27118284 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (Group 1)
Number of subjects: 1600
Study 27118284 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 1600
Study 27118284 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 3)
Number of subjects: 1600
Study 27118452 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy (first-generation CD19 CAR with CD3ζ endodomain) in NHL1, infused at doses of 25 to 200 × 10(6) cells.
Number of subjects: 16
Study 27118452 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy (second-generation CD19 CAR with CD28 and CD3ζ endodomains) in NHL2, infused at doses of 25 to 200 × 10(6) cells.
Number of subjects: 16
Study 27118481 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Number of subjects: 18
Study 27118540 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol (30 mg/m² loading dose followed by 30 mg/m² infusion once weekly for 3 weeks every 5 weeks for 2 cycles)
Number of subjects: 10
Study 27118956 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge transitional care programme (multidisciplinary integrated care team and early review in the clinic)
Number of subjects: 840
Study 27118956 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge transitional care programme
Number of subjects: 840
Study 27118956 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 840
Study 27119127 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Electronic Self-Report Assessment – Cancer intervention (symptom self-monitoring, tailored education, and communication coaching)
Number of subjects: 663
Study 27119127 — intervention group
Group type: COMPARATOR
Intervention: Usual care with symptom self-monitoring alone
Number of subjects: 663
Study 27120200 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2C LGMD
Number of subjects: 34
Study 27120200 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2D LGMD
Number of subjects: 34
Study 27120200 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2C and 2D LGMD
Number of subjects: 34
Study 27120200 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics
Number of subjects: 34
Study 27121168 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroischaemic patients (Isc)
Number of subjects: 70
Study 27121168 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic patients (Neu)
Number of subjects: 70
Study 27121168 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic volunteers
Number of subjects: 70
Study 27121209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 152
Study 27121782 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-756050 (various doses)
Number of subjects: 51
Study 27121782 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-756050 (two lowest doses)
Number of subjects: 51
Study 27121782 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-756050 (two highest doses)
Number of subjects: 51
Study 27121782 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-756050 + sitagliptin
Number of subjects: 51
Study 27121782 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg single dose on Day 6)
Number of subjects: 51
Study 27121890 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal correlates (age, education, BMI, income, milk feeding practices, ethnicity)
Number of subjects: 1237
Study 27121890 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant correlates (gender, birth order, infant body size gain)
Number of subjects: 1237
Study 27121890 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal correlates
Number of subjects: 1237
Study 27121948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-flagellin IgA in the highest quartile at 6 weeks of age
Number of subjects: 590
Study 27121948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LPS IgA in the highest quartile at 6 weeks of age
Number of subjects: 590
Study 27121948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-flagellin IgG in the highest quartile at 6 weeks of age
Number of subjects: 590
Study 27121948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LPS IgG in the highest quartile at 6 weeks of age
Number of subjects: 590
Study 27121948 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of anti-flagellin IgA
Number of subjects: 590
Study 27121948 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the markers (anti-flagellin IgA, anti-LPS IgA, anti-flagellin IgG, anti-LPS IgG)
Number of subjects: 590
Study 27122492 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher aldosterone levels
Number of subjects: 27
Study 27122492 — intervention group
Group type: COMPARATOR
Intervention: Lower aldosterone levels
Number of subjects: 27
Study 27122675 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan-based chemotherapy
Number of subjects: 120
Study 27122675 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A1*28 polymorphism
Number of subjects: 120
Study 27123488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dystonia patients
Number of subjects: 1000
Study 27124184 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 4680
Study 27124184 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression in normotensive women
Number of subjects: 4680
Study 27124184 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 4680
Study 27124184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication usage
Number of subjects: 4680
Study 27124248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 0
Study 27124248 — intervention group
Group type: COMPARATOR
Intervention: Limb immobilization
Number of subjects: 0
Study 27124254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer coaching and nurse case management
Number of subjects: 0
Study 27124254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer coaching
Number of subjects: 0
Study 27124254 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nurse counseling
Number of subjects: 0
Study 27124254 — intervention group
Group type: COMPARATOR
Intervention: Usual care control treatment (including brief peer coaching and brief nurse counseling)
Number of subjects: 0
Study 27124254 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (including control)
Number of subjects: 0
Study 27124486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg, twice daily) and trametinib (2 mg/d) continuously until disease progression or intolerance
Number of subjects: 23
Study 27124486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib treatment
Number of subjects: 23
Study 27124715 — intervention group
Group type: EXPERIMENTAL
Intervention: Common single nucleotide polymorphisms (SNPs)
Number of subjects: 1558
Study 27124835 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg daily for 21 days every 28 days)
Number of subjects: 60
Study 27125227 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization with embryo cryopreservation before live donor uterus transplantation (UTx). Induction immunosuppression. Embryo transfer 12 months after UTx.
Number of subjects: 1
Study 27125227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section performed at 34+6 weeks gestation.
Number of subjects: 1
Study 27125227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy performed 3.5 months after delivery.
Number of subjects: 1
Study 27125511 — intervention group
Group type: EXPERIMENTAL
Intervention: FDCA (Fusiform dilatation of the internal carotid artery)
Number of subjects: 583
Study 27125511 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after FDCA detection
Number of subjects: 583
Study 27125511 — intervention group
Group type: COMPARATOR
Intervention: Survival rates and functional capacity
Number of subjects: 583
Study 27125892 — intervention group
Group type: EXPERIMENTAL
Intervention: Liletta® 52-mg IUS
Number of subjects: 100
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay counsellor clinic linkage facilitation
Number of subjects: 2339
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay counsellor follow-up home visits
Number of subjects: 2339
Study 27126488 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic referral
Number of subjects: 2339
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 2339
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay counsellor follow-up visits
Number of subjects: 2339
Study 27126488 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic referral for circumcision
Number of subjects: 2339
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ART initiation
Number of subjects: 2339
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care for HIV-positive participants
Number of subjects: 2339
Study 27126488 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit to circumcision facility
Number of subjects: 2339
Study 27126489 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status awareness
Number of subjects: 12610
Study 27126489 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 12610
Study 27126489 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load measurement
Number of subjects: 12610
Study 27126489 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological suppression
Number of subjects: 12610
Study 27127635 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 10568
Study 27127635 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-ACS
Number of subjects: 10568
Study 27127635 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-ACS with prior CVD
Number of subjects: 10568
Study 27127635 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-ACS without prior CVD
Number of subjects: 10568
Study 27127635 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource use
Number of subjects: 10568
Study 27128217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 27128217 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0
Study 27128233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg, followed by 200 mg QD for days 2-7) plus tofacitinib (30 mg on day 5)
Number of subjects: 24
Study 27128233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg QD for days 1-3) plus tofacitinib (10 mg on day 3)
Number of subjects: 24
Study 27128358 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPLe smartphone application
Number of subjects: 51
Study 27128614 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (1-4 mg daily oral maintenance doses)
Number of subjects: 24
Study 27128675 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (days 0-2) plus single dose primaquine (0.75mg/kg on day 2) for P. falciparum infections
Number of subjects: 181
Study 27128675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (days 0-2) plus 14 days primaquine (3.5mg/kg total over 14 days) for P. vivax infections
Number of subjects: 181
Study 27128675 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 181
Study 27128675 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD activity measurement
Number of subjects: 181
Study 27129014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole granules
Number of subjects: 130
Study 27129014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole granules (to-be-marketed)
Number of subjects: 130
Study 27129014 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole tablets
Number of subjects: 130
Study 27129117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg single dose in subjects with mild hepatic impairment
Number of subjects: 18
Study 27129117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg single dose in subjects with moderate hepatic impairment
Number of subjects: 18
Study 27129125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 30 mg twice daily
Number of subjects: 24
Study 27129125 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg
Number of subjects: 24
Study 27129325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) using an autologous CD34(+)-enriched cell fraction transduced with a retroviral vector encoding human ADA cDNA (GSK2696273)
Number of subjects: 18
Study 27129325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT)
Number of subjects: 18
Study 27129602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Activity Monitors (EAM)
Number of subjects: 40
Study 27129602 — intervention group
Group type: COMPARATOR
Intervention: Pedometer
Number of subjects: 40
Study 27129602 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM
Number of subjects: 40
Study 27130216 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-staffed EMS
Number of subjects: 458
Study 27130216 — intervention group
Group type: COMPARATOR
Intervention: Paramedic-staffed EMS
Number of subjects: 458
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. methylprednisolone
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical decompression
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: blood pressure augmentation
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: minocycline
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: fibroblast growth factor
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium
Number of subjects: 0